Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications - PubMed (original) (raw)

. 2005 Apr;446(4):442-50.

doi: 10.1007/s00428-005-1212-8. Epub 2005 Mar 23.

Affiliations

Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications

Wilko Weichert et al. Virchows Arch. 2005 Apr.

Abstract

Polo-like kinase (PLK) family members are known to be functionally involved in mitotic signaling and in cytoskeletal reorganization in both normal and malignant cells. In this study, expression of PLK1 and PLK3 was determined immunohistochemically in tissue specimens of 135 breast carcinomas, and expression was correlated with clinicopathological parameters and patient prognosis. Strong PLK isoform overexpression was observed in 42.2% (PLK1) and 47.4% (PLK3) of breast carcinomas when compared with non-transformed breast tissue. A positive correlation of PLK isoform expression with tumor grade, vascular invasion, erbB2/HER-2 expression and markers of proliferative activity was evident. Additionally, an inverse correlation of PLK isoform expression and estrogen receptor status was observed. Overexpression of PLK3 but not of PLK1 was significantly linked to reduced median overall (P<0.001) and relapse-free (P=0.021) survival time. PLK3 expression remained an independent prognostic factor for overall (RR=3.2, P=0.002) and relapse-free (RR=2.9, P=0.049) survival in multivariate survival analysis. These results suggest PLK3 as a novel independent prognostic marker in breast cancer and hint toward a role for PLK isoform overexpression in disease progression. Therefore, in vivo inhibition of PLK family members might represent a rewarding approach in the development of new anticancer drugs for this tumor entity.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Cutan Pathol. 2002 Jul;29(6):354-8 - PubMed
    1. Oncogene. 2002 Sep 9;21(40):6195-200 - PubMed
    1. Cancer Res. 1999 Jun 15;59(12):2794-7 - PubMed
    1. Mol Cell. 2002 Mar;9(3):515-25 - PubMed
    1. Semin Oncol. 2003 Oct;30(5 Suppl 16):38-48 - PubMed

MeSH terms

Substances

LinkOut - more resources